Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CALVARUSO, Vincenza
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.329
EU - Europa 6.047
AS - Asia 5.956
SA - Sud America 927
AF - Africa 167
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 12
Totale 26.463
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.094
SG - Singapore 2.244
RU - Federazione Russa 1.784
IT - Italia 1.465
CN - Cina 1.347
BR - Brasile 747
HK - Hong Kong 581
VN - Vietnam 533
FI - Finlandia 493
BD - Bangladesh 455
DE - Germania 443
PL - Polonia 384
FR - Francia 289
GB - Regno Unito 277
UA - Ucraina 277
IE - Irlanda 204
JP - Giappone 166
IN - India 133
CA - Canada 112
KR - Corea 106
SE - Svezia 96
MX - Messico 65
NL - Olanda 64
AR - Argentina 62
AT - Austria 50
IQ - Iraq 49
RO - Romania 49
TR - Turchia 49
ES - Italia 39
BE - Belgio 36
ZA - Sudafrica 36
PK - Pakistan 33
UZ - Uzbekistan 30
ID - Indonesia 29
CI - Costa d'Avorio 28
VE - Venezuela 28
AU - Australia 21
AZ - Azerbaigian 21
EC - Ecuador 21
EG - Egitto 21
MA - Marocco 21
AE - Emirati Arabi Uniti 20
PY - Paraguay 19
KE - Kenya 18
SA - Arabia Saudita 18
JO - Giordania 17
PH - Filippine 16
IR - Iran 15
MY - Malesia 15
CH - Svizzera 14
CO - Colombia 14
LT - Lituania 12
UY - Uruguay 12
JM - Giamaica 11
DZ - Algeria 10
GR - Grecia 10
PT - Portogallo 10
TW - Taiwan 10
CL - Cile 8
CZ - Repubblica Ceca 8
DO - Repubblica Dominicana 8
IL - Israele 8
NP - Nepal 8
TN - Tunisia 8
BG - Bulgaria 7
BO - Bolivia 7
EU - Europa 7
GT - Guatemala 7
KZ - Kazakistan 7
OM - Oman 7
HN - Honduras 6
KG - Kirghizistan 6
LB - Libano 6
PE - Perù 6
SN - Senegal 6
BY - Bielorussia 5
DK - Danimarca 5
TH - Thailandia 5
AO - Angola 4
CR - Costa Rica 4
EE - Estonia 4
GE - Georgia 4
KY - Cayman, isole 4
NZ - Nuova Zelanda 4
RS - Serbia 4
TT - Trinidad e Tobago 4
AL - Albania 3
BH - Bahrain 3
BN - Brunei Darussalam 3
NG - Nigeria 3
NI - Nicaragua 3
PA - Panama 3
SI - Slovenia 3
SV - El Salvador 3
SY - Repubblica araba siriana 3
TG - Togo 3
XK - ???statistics.table.value.countryCode.XK??? 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BB - Barbados 2
CM - Camerun 2
Totale 26.429
Salva come PNG Salva come JPEG
Città #
Ashburn 1.743
Fairfield 1.688
Singapore 1.534
Woodbridge 806
San Jose 703
Houston 700
Seattle 670
Wilmington 638
Chandler 635
Cambridge 584
Hong Kong 557
Ann Arbor 381
Zgierz 341
Moscow 307
Palermo 264
Medford 228
Council Bluffs 225
New York 220
Los Angeles 214
Beijing 203
Dublin 202
Altamura 191
Ho Chi Minh City 182
Helsinki 176
Lauterbourg 156
Santa Clara 156
Tokyo 152
Des Moines 149
Princeton 142
Hanoi 136
Lawrence 134
Nanjing 133
Jacksonville 123
Dallas 108
San Diego 102
Frankfurt am Main 98
The Dalles 95
Boardman 92
Hefei 91
Buffalo 84
Milan 74
Rome 73
London 69
Dearborn 68
São Paulo 68
Tulsa 55
Phoenix 53
Orem 50
Shenyang 50
Nuremberg 49
Ludwigshafen am Rhein 48
Chicago 46
Tianjin 41
Hebei 38
Nanchang 35
Warsaw 35
Changsha 34
Jinan 33
Brussels 31
Columbus 29
San Paolo di Civitate 29
Abidjan 28
Paris 28
Toronto 28
Jiaxing 27
Lappeenranta 27
Amsterdam 26
Chennai 26
Redwood City 25
Saint Petersburg 25
Haiphong 24
Da Nang 23
Mumbai 23
Munich 23
Bologna 22
Ningbo 22
Tashkent 22
Brooklyn 21
Florence 21
Montreal 21
Baghdad 20
Falls Church 20
Seongnam 20
Atlanta 19
Baku 19
Denver 18
Johannesburg 18
Zhengzhou 18
Nairobi 17
Ottawa 17
Salt Lake City 17
San Francisco 17
Shanghai 17
Vienna 17
Guangzhou 16
Hangzhou 16
Porto Alegre 16
Seoul 16
Stockholm 16
Venice 16
Totale 17.163
Salva come PNG Salva come JPEG
Nome #
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis 393
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals 325
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension 293
Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication. 273
Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis 271
Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects 263
Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis 260
Clinical implications of the hyperdynamic syndrome in cirrhosis. 257
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. 247
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 246
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. 243
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial 240
The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance 240
Baveno VII – Renewing consensus in portal hypertension 234
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 229
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D. 228
Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance 227
IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. 226
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. 222
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 211
A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation. 210
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 210
Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients 210
Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. 208
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension:a randomized controlled trial 204
Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis 203
Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients 200
Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy 198
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin 198
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 198
The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis 196
The impact of sustained virological response on clinical outcomes in compensated HCV cirrhosis: a prospective cohort study 195
Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease 195
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents 194
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 194
Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. 193
Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? the REAL Experience 193
AISF position paper on liver disease and pregnancy. 192
CLINICAL COURSE OF NIMESULIDE-INDUCED LIVER INJURY 189
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. 189
Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach 187
Hepatocellular carcinoma and direct-acting antivirals: A never ending story? 186
Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication? 185
HCV CLEARANCE AFTER PEG IFN PLUS RBV IMPROVES THE COURSE OF HCV CIRRHOSIS REGARDLESS OF PORTAL HYPERTENSION 184
Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study) 184
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 184
Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis 183
A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort 182
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 182
Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy 181
Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis 180
Critically ill patients with cirrhosis and low serum sodium. 180
An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers 178
Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis 178
A rs4374383 Single Nucleotide Polymorphisms of MERTK gene is linked to a higher likelihood of hepatocellular carcinoma in patients with HCV cirrhosis 178
Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis 178
Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference 175
The impact of sustained virological response on clinical outcome in compensated HCV cirrhosis: a prospective cohort study 174
Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis 173
Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study 172
Impact of Tips Preliver Transplantation for the Outcome Posttransplantation 169
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). 169
Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation 167
Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model 166
Histological subclassification of cirrhosis 165
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 165
Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation 164
Meccanismi immunologici e molecolari del danno epatico da farmaci 162
Hepatitis C virus eradication by direct antiviral agents abates oxidative stress in patients with advanced liver fibrosis 161
Implication of Normal Liver Enzymes in Liver Disease 159
Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience 158
NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. 157
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication 157
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 156
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? 156
TACE versus TAE as therapy for hepatocellular carcinoma. 155
Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation. 155
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 155
The effect of antiviral therapy on clinical outcome of HCV cirrhosis with portal hypertension: a prospective cohort study. 153
PEG-interferon plus Ribavirin in compensated HCV cirrhosis with portal hypertension: the role of rapid and early virological response in predicting the sustained virological response 153
Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model 152
Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy 152
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. 150
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 149
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. 148
Risk of disease decompensation and HCC in patients with HCV cirrhosis non responders to PEG IFN plus RBV 146
Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP) 146
Hepassocin as a treatment for fulminant hepatic failure: will it translate from rats to human? 144
LIVER RELATED EVENTS AND SURVIVAL IN PATIENTS WITH COMPENSATED HCV CIRRHOSIS: THE ROLE OF SUSTAINED VIROLOGICAL RESPONSE TO PEG-IFN BASED THERAPY AND PORTAL HYPERTENSION 144
Coagulation and fibrosis in chronic liver disease. 143
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 143
Fibrosis in chronic viral hepatitis 143
PEG_interferon plus Ribavirin in compensated HCV cirrhosis with portal hypertension: the role of rapid and early virological response in predicting the sustained virological response 142
Computer-Assisted Image Analysis of Liver Collagen: Relationship to Ishak Scoring and Hepatic Venous Pressure Gradient 142
Predictors of Re‐bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic Shunt (TIPS) 142
RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. 139
Fecal calprotectin in clinical practice: a noninvasive screening tool for patients with chronic diarrhea 139
Models for non-alcoholic fatty liver disease: a link with vascular risk. 138
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 138
Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. 138
Totale 18.781
Salva come PNG Salva come JPEG
Categoria #
all - tutte 98.870
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 98.870
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021192 0 0 0 0 0 0 0 0 0 0 0 192
2021/20221.752 58 318 149 53 46 67 132 115 213 163 148 290
2022/20232.133 212 488 39 186 247 298 119 148 246 16 73 61
2023/2024922 39 106 82 55 80 226 102 48 18 24 28 114
2024/20252.869 95 244 141 240 84 156 194 144 220 365 359 627
2025/202611.247 679 300 604 909 1.065 1.539 1.439 1.247 1.023 1.094 680 668
Totale 27.296